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Abstract. The regulation of human Factor IX.
was studied in vitro in human and mouse plasma and
in vivo in the mouse. In human plasma, -60% of the
'251-Factor IX8 was bound to antithrombin III (ATIII) by
2 h, with no binding to a2-macroglobulin or aI-proteinase
inhibitor, as assessed by gel electrophoresis and IgG-an-
tiproteinase inhibitor-Sepharose beads. In the presence
ofheparin, virtually 100% ofthe 125I-Factor IXa was bound
to ATIII by 1 min. The distribution of '25I-Factor IXa in
mouse plasma was similar. The clearance of '25I-Factor
IXa was rapid (50% clearance in 2 min) and biphasic and
was inhibited by large molar excesses of ATIII-thrombin
and a,-proteinase inhibitor-trypsin, but not a2-macro-
globulin-trypsin; it was also inhibited by large molar ex-
cesses of diisopropylphosphoryl- (DIP-) Factor Xa, DIP-
thrombin, and Factor IX, but not by prothrombin or
Factor X. The clearance ofFactor IX was also rapid (50%
clearance in 2.5 min) and was inhibited by a large molar
excess of Factor IX, but not by large molar excesses of
Factor X, prothrombin, DIP-Factor Xa, or DIP-thrombin.
Electrophoresis and IgG-antiproteinase inhibitor-Se-
pharose bead studies confirmed that by 2 min after in-
jection into the murine circulation, 60% ofthe 125I-Factor
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IXa was bound to ATIII. Organ distribution studies with
'25I-Factor IXa demonstrated that most ofthe radioactivity
was in the liver. These studies suggest that Factor IXa
binds to at least two classes ofbinding sites on endothelial
cells. One site apparently recognizes both Factors IX and
IXa, but not Factor X, Factor Xa, prothrombin, or
thrombin. The other site recognizes thrombin, Factor Xa,
and Factor IXa, but not the zymogen forms of these
clotting factors. After this binding, Factor IXa is bound
to ATIII and the complex is cleared from the circulation
by hepatocytes.
introduction
Factor IX is a vitamin K-dependent coagulation protein that
can be activated by both the intrinsic and extrinsic pathways
(1). Localization of the reactions of the coagulation cascade to
the site of vascular injury and the regulation of the activated
coagulation factors are important in thrombosis and hemostasis.
Recently, Factors IX and IXa (the activated form of Factor IX)
were shown to bind to the same site on endothelial cells in
tissue culture (2, 3). Factor X, prothrombin, and thrombin did
not bind to this endothelial cell site. Endothelial cell binding
may serve to localize clot-promoting activity, as bound Factor
IXa has at least three times the procoagulant activity of Factor
IXa in solution (3).
Relatively little is known about the regulation of Factor IXa
by the plasma proteinase inhibitors, other than antithrombin
III (ATIII).' Bovine and human Factor IXa have been shown
to react slowly with ATITI, forming a stable 1:1 stoichiometric
complex. This reaction is greatly accelerated in the presence of
heparin (4-7). The reactions ofFactor IXa with a2-macroglobulin
1. Abbreviations used in this paper: ATIII, antithrombin III; a2M, a2-
macroglobulin; alPI, a1-proteinase inhibitor (a,-antitrypsin); DIP-, di-
isopropylphosphoryl-.
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(a2M) and aI-proteinase inhibitor (aIPI) have not been described.
The present studies were undertaken to examine the regulation
of human Factor IXa in vivo. The distribution of '251-Factor
IXa among the plasma proteinase inhibitors in human plasma
in vitro was examined by sodium dodecyl sulfate- (SDS-) poly-
acrylamide gel electrophoresis and by IgG-antiproteinase in-
hibitor-Sepharose beads. These results were compared with those
obtained from mouse plasma, and the in vivo regulation of
Factor IXa was then studied using our previously described
mouse model. We have recently shown that Factor Xa binds
to an endothelial cell thrombin-binding site; this binding alters
the proteinase inhibitor specificity of Factor Xa such that a2M
is the primary in vivo inhibitor of Factor Xa, whereas a1PI is
the primary in vitro inhibitor of Factor Xa (8). In light of these
results, the endothelial binding of Factor IXa and the possible
role of this binding in the regulation ofFactor IXa were examined
in vivo in our mouse model.
Methods
Reagents. Reagents were obtained as previously described (8).
Proteins. Human Factor IX was purified as previously described (9).
Human prothrombin and Factor X were prepared by the method of
Miletich et al. (10). Human a-thrombin (specific activity 2,700 U/mg),
DIP-thrombin, Factor Xa, and DIP-Factor Xa were prepared as previously
described (8, 11, 12). Diisopropylfluorophosphate (20 mM) failed to
inhibit Factor IXa, even after reaction for 6 or 24 h; this is consistent
with previous studies (6). Human Factor XIa was prepared as described
by Chung et al. (9) and used to activate Factor IX as previously described
(13). Activation was 80-85% complete by 90 min, as determined by
SDS-polyacrylamide gel electrophoresis under reducing conditions. a2M,
ATIII, and ajPI were purified from human plasma as previously reported
(11, 14, 15). Mouse ATIII was prepared essentially as described for
human ATIII (1 1).
Trypsin was purchased from Worthington Biochemicals (Freehold,
NJ) and was 70% active, as determined by active site titration (16).
Trypsin complexes of a2M, a1PI, and ATII were prepared as previously
described (8).
Protein concentration. The concentrations of purified proteins were
determined using the extinction coefficients and molecular weights pre-
viously reported (6, 10, 11, 17-23).
Protein radiolabeling. Human a2M, a1PI, and ATIII, and mouse
ATIII were radiolabeled with 1251 by the solid state lactoperoxidase method
(24). Radioactivity was measured in a gamma counter (AW14-120;
Scientific Products, American Hospital Supply Corp., McGaw Park,
IL). Proteins were labeled to specific radioactivities of 1,000-2,000 cpm/
ng and assayed for activity. a2M was assayed by the method of Ganrot
(25). a1PI was assayed as described by Dietz et al. by measuring the
inhibition of the hydrolysis of a-N-benzoyl-DL-arginine-p-nitroanilide
by trypsin (26). ATIII activity was determined as the inhibition of the
thrombin-catalyzed hydrolysis of the chromogenic substrate S-2238 (27).
In all cases, proteins retained at least 95% activity after radiolabeling.
Human Factor IX was radiolabeled with 1251 using Iodobeads (Pierce
Chemical Co., Rockford, IL) in 50 mM Tris-HCl, 0.15 M NaCl, pH
7.4. Typically, 100 Ag Factor IX was incubated with 1.5 mCi 1251I and
two beads at room temperature for 30 min with mixing. Specific ra-
dioactivities of 1,000-1,500 cpm/ng were routinely obtained. The ra-
diolabeled Factor IX displayed activity identical to that of the unlabeled
Factor IX, both species being 80-85% activated by Factor XI. in the
presence of Ca"t ions, as assessed by SDS-polyacrylamide gel electro-
phoresis under reducing conditions.
Polyacrylamide gel electrophoresis. SDS-polyacrylamide gel electro-
phoresis of purified protein samples was performed using 5 and 7.5%
acrylamide slab gels as described by Wycoff et al. (28). SDS-polyacryl-
amide gel electrophoresis of plasma samples was performed on 5% slab
gels according to the method of Weber and Osborn (29). 25-Al plasma
samples were denatured in 75 Al 6% SDS at 950C for 2 min. After
drying, gels containing radioactivity were placed against Kodak XAR-
2 film (Cardinal X-ray, Winston-Salem, NC) with an image-intensifying
screen overnight at -70'C to prepare autoradiograms. Gel lanes were
then sliced into sections 3 mm long in the direction of migration and
the radioactivity in each slice was measured in agamma counter. Protein
content was then calculated using the previously determined specific
radioactivities of the preparations. Gel profiles were plotted and relative
peak areas were obtained by cutting and weighing the peaks.
Reaction of Factor IXa with purified plasma proteinase inhibitors.
Factor IX. and "25I-Factor IX, were incubated with human a2M, a1P1,
and ATIII, and with mouse ATIII for 2 h at 230 and 370C in equimolar
ratios and at proteinase inhibitor excess. The degree ofcomplex formation
was then determined by SDS-polyacrylamide gel electrophoresis, ac-
cording to the method of Weber and Osborn (29), as described above,
to assess the degree of covalent binding of '25I-Factor IX. to each inhibitor
and to establish reference markers for the in vitro experiments with
mouse and human plasma and for the in vivo clearance studies. In
several experiments, the mixture resulting from the incubation of 12511
Factor IXa was subjected to chromatography on Ultrogel AcA22 (LKB
Instruments Inc., Gaithersburg, MD) before electrophoresis.
IgG-antiproteinase inhibitor-Sepharose beads. The IgG fraction of
goat antihuman a2M, a1PI, or ATIII was coupled to CNBr-activated
Sepharose 4B CL as previously described (8). The beads were charac-
terized by incubating 50 ,ul of the resultant IgG-Sepharose preparations
with 1-500 jg '25I-labeled human a2M, a1PI, and ATIII, and mouse
ATIII, or with the corresponding '251-proteinase inhibitor-trypsin complex
in 500 Ml of 50 mM Tris-HCI, 0.15 M NaCl, 60 mg/ml bovine serum
albumin, pH 7.40, at 37°C for 2 h with constant mixing in a series of
saturation curves. The tubes were then centrifuged in an Eppendorf
microcentrifuge. The supernatants were removed and the beads were
washed three times with cold Tris buffer (1 ml each). The bottoms of
the tubes were cut offand the radioactivity content in beads, supernatants,
and washes was determined. Under the conditions chosen for the ex-
periments described below, 80-900% of the applied '251-labeled proteinase
inhibitors bound to the corresponding IgG-Sepharose, with 1.5% non-
specific binding, as determined by incubating the noncorresponding
inhibitors with a given IgG-Sepharose sample. The binding of the pro-
teinase inhibitors to their corresponding IgG-Sepharoses was virtually
unaffected by the formation oftrypsin complexes before incubation with
the beads. 1251-Factor IX. was also incubated with the IgG-Sepharoses;
maximal binding of this ligand to any of the IgG-Sepharose preparations
was 12%.
Mouse plasma. Mouse plasma for in vitro studies was obtained by
incising anesthetized mice in the midline and cannulating the inferior
vena cava. Blood was drawn into syringes containing 0.1 vol 3.8% sodium
citrate and centrifuged immediately. The plasma was drawn off and
used in experiments within 1 h of bleeding.
Plasma studies in vitro. Citrated human or mouse plasma (250 Ml)
was incubated with 1 Atg '251-Factor IX. at 37°C. Samples (25 Al) were
removed at various times and either incubated with IgG-Sepharose beads
in 500 Ml of 50 mM Tris-HCl, 0.15 M NaCl, 60 mg/ml albumin, pH
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7.40, as described above, or denatured immediately for SDS-gel elec-
trophoresis.
Plasma elimination studies. Plasma elimination studies of '25I-Factor
IX and '25I-Factor IX. (0.5 to I ug) alone or in the presence of large
molar excesses of unlabeled proteins were performed in CD-1 female
mice, as previously described (8). To examine the distribution of Factor
IX. between the plasma and the cellular elements of blood, 125I-Factor
IX. was injected and 800 Ml of blood was collected after 5 min into 0.1
vol 3.8% sodium citrate. The sampled blood was centrifuged at 10,000
g for 10 min at 4VC to pellet the cellular elements and the supernatant
plasma was removed with a pipette. The cellular pellet was washed three
times with 1 ml cold 0.05 M Hepes, 0.15 M NaCl, pH 7.40, and the
radioactivity content of the plasma, washes, and the cellular pellet was
determined. In some plasma elimination studies, duplicate samples were
taken at each time point. One sample was counted in a gamma counter,
the other was drawn into 0.1 vol 3.8% sodium citrate and centrifuged
immediately at 4VC. The plasma was then denatured immediately for
SDS-gel electrophoresis. In general, studies were performed at least four
times.
Tissue distribution studies. Organ distribution studies were performed
as previously described after injection of 5 1g of I251-ligand (30).
Results
Reaction ofFactor IXa with purifiedplasma proteinase inhibitors.
There was no evidence of complex formation of either Factor
IXM or '251I-Factor IX, with a2M or a1PI after 2 h at 230C or
37°C, as assessed by SDS-polyacrylamide gel electrophoresis
(data not shown). With human or mouse ATIII, -50% of the
Factor IXa or 251I-Factor IXa had been converted to the ATIII
complex by 2 h at 23°C or 37°C. In the presence of heparin
(10 U/ml), the conversion of Factor IX. or '251I-Factor IX, to
the complex with either human or mouse ATIII was virtually
100% complete by 1 min at either 23° or 37°C (data not shown).
In vitro distribution of Factor IXa among the proteinase
inhibitors in human and mouse plasma. The time course of
inactivation of "25I-Factor IX, in human and mouse plasma
was studied using SDS-polyacrylamide gel electrophoresis. The
results obtained with human and mouse plasma were virtually
identical; the time course of inactivation of 125I-Factor IX, in
mouse plasma is shown in Fig. 1, lanes a-i, for comparison
with the in vivo results described below. Complexes of c2M
and proteinase would be seen at the top of the gel lanes if they
were present. The results for both human and mouse plasma
are summarized in Table I. Approximately 60% of the 12511
Factor IX, was bound to ATIII by 2 h, with no binding to a2M
in either human or mouse plasma. From these data, based on
the use of 1 Mg of 251I-Factor IX. and 250 Ml of plasma, it is
possible to calculate the rate of inhibition of Factor IX, by
ATIII. Both human and mouse ATIII inhibited -0.02 Mg of
human Factor IX./ml plasma per min. In the presence ofheparin
(10 U/ml), virtually 100% of the '251I-Factor IX, was bound to
ATIII by 1 min (Table I).
IgG-antiproteinase inhibitor-Sepharose bead studies. Samples
of human plasma, after 2 h of incubation with 251I-Factor IXa,
were mixed with goat IgG-antihuman a2M, a1PI, or ATIII co-
- AT m - Factor IXa
Factor iX
uwaiw_ _ w w o s vo _-Factor 1Xa
- Activation Peptide
ci cd e g ri
Figure 1. In vitro and in vivo distribution of '25I-Factor IXa in
mouse plasma. SDS-polyacrylamide gel electrophoresis of 1 ug 1251I
Factor IX. incubated with: (a-i) 250 MAl citrated mouse plasma for
various times (a, 0; b, 1; c, 5; d, 10; e, 20;4 30; g, 60; h, 90; i, 120
min) or (j) injected into a mouse, with plasma collected after 2 min.
valently linked to Sepharose. The experiment was repeated in
the presence of heparin (10 U/ml) after 1 min of incubation of
251I-Factor IXa with the heparinized plasma (Table II). The ex-
periments were repeated with mouse plasma in the presence
and absence of heparin (10 U/ml) using only the anti-ATIII-
Sepharose beads. The results are essentially identical to those
obtained with human plasma and are shown in Table II. These
results show that ATIII is the primary inhibitor of Factor IX.
in vitro in human and mouse plasma, although in the absence
of heparin the reaction is slow.
Plasma elimination of Factor IX. The clearance curve of
125i-Factor IX is biphasic (Fig. 2 A), with an initial rapid dis-
Table I. In Vitro Distribution of'25I-Factor IXa in Human








Plasma conditions a2M ATIII Free Factor IX.
Human 2 h 0 62.8 37.2
no heparin
1 min 0 99.5 0.5
+ heparin
Mouse 2 h 0 60.5 39.5
no heparin
1 min 0 99.0 1.0
+ heparin
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Table II. In Vitro Distribution of 125I-Factor IXa in Human and
Mouse Plasma Determined by Adsorption ofIgG-Sepharose
Antiserum to inhibitor
(% total binding)
Incubation Free Factor IX.
Plasma conditions a2M a1PI ATIII (% total)
Human 2 h 0 0 64.3 35.7
no heparin
1 min 0 0 98.7 1.3
+ heparin




appearance of protein followed by a slow phase of longer du-
ration. Blood from one experimental animal sampled 10 min
after injection of '251-Factor IX was reinjected into a second
animal. The reinjected blood cleared identically (Fig. 2 A), thus
mediating against a rapidly clearing subpopulation of modified
Factor IX or contaminants. A 2,000-fold molar excess of un-
labeled Factor IX inhibited the clearance of labeled Factor IX,
prolonging the half-life of '251I-Factor IX from 2 to 10 min (Fig.
2). These results suggest that Factor IX is rapidly cleared from
the circulation, probably owing to endothelial cell binding as
previously described in vitro (3). The slow late phase ofclearance
probably results from equilibration of the injected Factor IX
with the murine Factor IX pool. To establish the specificity of














with Factor X and prothrombin. Even at a 2,000-fold molar
excess, neither species inhibited the clearance of '251-Factor IX
(Fig. 2 A). Competition experiments were also performed with
DIP-Factor Xa and DIP-thrombin, with no inhibition of the
clearance of '251I-Factor IX, even at 2,000-fold molar excesses
(Fig. 2 B).
Plasma elimination of Factor IXa. The clearance of 125i-
Factor IXa was rapid and biphasic (Fig. 3 A). To further char-
acterize the clearance of Factor IX., competition experiments
were performed with unlabeled Factor IX, Factor X, prothrom-
bin, DIP-Factor Xa, and DIP-thrombin (Fig. 3, A and B). Among
the zymogens, only Factor IX inhibited the clearance of 12511
Factor IXa, indicating that Factor IX and Factor IX. are cleared
by a site that recognizes both the zymogen and the activated
species. Both DIP-thrombin and DIP-Factor Xa also inhibited
the clearance of 1251-Factor IXa at 2,000-fold molar excess. These
results indicate that Factor MXa binds to the high affinity en-
dothelial cell thrombin-binding sites described by Lollar and
Owen (31), which we have recently shown also bind Factor
Xa (8).
In order to study directly the clearance of inactivated Factor
IXa, an attempt was made to prepare DIP-Factor IXa. Previous
studies by Davie and colleagues (6) suggested that human Factor
IX5 is not inhibited by diisopropylfluorophosphate. In the present
study, Factor IXa was treated with this reagent at a concentration
of 20 mM for either 6 or 24 h. There was no loss of Factor IXa
activity as compared with a control preparation of Factor IX.
incubated under similar conditions in the absence of the in-
hibitor. This contrasts markedly with trypsin, which in 15 min
is completely inactivated at a I mM concentration of diisopro-
pylfluorophosphate. Thrombin is also rapidly inhibited under
these reaction conditions (31). Therefore, it was impossible to
study the clearance of DIP-Factor IXa.
The possibility that the cellular elements of blood are in-
B
Figure 2. Clearance from the circulation of intravenously
injected Factor IX. '25I-labeled protein (0.5-1.0 tig) was
injected into mice and blood samples were collected at
~----_G intervals. (A) '25I-Factor IX (.). Reinjection study of 125I
Factor IX (o). The clearance of 251-Factor IX in the
presence of 2,000-fold molar excesses of Factor IX (-),
Factor X (A), and prothrombin (o). (B) The clearance of
'25I-Factor IX in the presence of 2,000-fold molar ex-
cesses of DIP-Factor X. (e) or DIP-thrombin (o). The
50 60 clearance of Factor IX alone is shown as a dashed line
for comparison.
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Figure 3. Clearance from the circulation of intravenously
injected Factor IXa. Clearance studies as described in
Fig. 2. (A) '25I-Factor IXa (@). The clearance of '25I-Fac-
tor IXa in the presence of 2,000-fold molar excesses of
Factor IX (A), Factor X (A), or prothrombin (o). (B) The
clearance of '25I-Factor IX. in the presence of 2,000-fold
molar excesses of DIP-Factor Xa (a) or DIP-thrombin
(o). The clearance of Factor IXa alone is shown as a
dashed line for comparison.
volved in the catabolism of Factor IXa was investigated by in-
jecting 1251-Factor IXa into a mouse, collecting blood into 0.1
vol sodium citrate, separating the plasma and cellular elements
as described in Methods, and determining the radioactivity con-
tent ofeach. The cellular pellet contained 0.4% ofthe recovered
radioactivity; the remaining 99.6% was in the plasma.
The role ofthe plasma proteinase inhibitors in the catabolism
of Factor IXa was investigated using trypsin complexes of a2M
and aPI, and ATIII-thrombin. The clearance pathways for pro-
teinase complexes of these inhibitors have been characterized
in mouse (1 1, 14, 15). At a 2,000-fold molar excess, a2M-trypsin
failed to inhibit the clearance of Factor IXa (Fig. 4). At 2,000-
fold molar excesses, both ATIII-thrombin and alPI-trypsin in-
hibited the clearance of '251-Factor IXa, with a1PI-trypsin pro-
viding somewhat poorer competition. These results are consistent
with the clearance of proteinase complexes of ATIII and a1PI




Figure 4. Clearance from
* \ the circulation of intrave-
<40<40 A ~ _ nously injected Factor IXa.
Clearance studies are as de-
scribed in Fig. 2. The clear-
z ance of '25I-Factor IXa in
20 _ ~ ~~~~the presence of 2,000-fold
molar excesses of ATIII-
thrombin (.), a1PI-trypsin
(o), and a2M-trypsin (A).
The clearance of '251-Factor
10 20 30 40 50 4o IX. alone is shown as a
TIME (min) dashed line for comparison.
To characterize further the proteinase inhibitor-dependent
phase of Factor IXa clearance, complexes of human ATIII-'251-
Factor IXa were prepared and used in clearance studies (Fig.
5). The clearance of ATIII-'251-Factor IXa was extremely rapid
(50% clearance in 1.5 min). The clearance of ATIII-'251-Factor
IXa was inhibited by 2,000-fold molar excesses ofATIII-throm-
bin and to a slightly lesser degree by a1PI-trypsin.
Organ distribution of l2SI-Factor IX and "2I-Factor IXa.
Radiolabeled Factor IX or Factor IXa was injected intravenously.
The distributions of radioactivity at 2 and 20 min are shown
in Table III. Both species are found predominantly in the liver.
In vivo distribution of '25I-Factor IXa among the plasma
proteinase inhibitors. A plasma sample obtained 2 min after
the injection of 1251I-Factor IXa was subjected to SDS-polyacryl-
amide gel electrophoresis (Fig. 1, lane j). By this time 50% of
the ligand had left the plasma compartment. The relative
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Figure 5. Clearance from
the circulation of intrave-
nously injected ATIII-'251-
Factor IXa complexes.
Clearance studies are as de-
scribed in Fig. 2. Clearance
of ATIII-'25I-Factor IX. (@).
Clearance of ATIII-'25I-Fac-
tor IXa in the presence of
2,000-fold molar excesses
of ATIII-thrombin (o) and
aPI-trypsin (A).












Table III. Organ Distribution of '251-Factor IX or '25I-Factor IXa
% Recovered dose
Factor IX Factor IX,
2 min 2 min 20 min
Heart 0.7 0.6 0.5
Lung 2.0 2.4 1.9
Spleen 5.3 4.0 4.2
Kidneys 5.5 7.7 10.4
Liver 86.0 85.0 83.0
Table IV. A duplicate plasma sample was incubated with IgG-
anti-ATIII-Sepharose beads, and the distribution of '251-Factor
IXa was calculated (Table IV). These results demonstrate that
nearly 60% of the recovered '251I-Factor IXa is in the form of
the complex with ATIII after 2 min, yielding a calculated rate
of inhibition of -0.1 ,ug human Factor IX,/ml plasma per min,
assuming a plasma volume of - 1.5 ml in the mouse (14).
Discussion
These studies were undertaken to elucidate the catabolism of
Factor IXa. Relatively little is known about the reaction of
Factor IXa with the plasma proteinase inhibitors, except for
ATIII. Factor IXa reacts slowly with ATIII in the absence of
heparin (4-7). The reactions of Factor IXa with a2M and a1PI
have not been described. These results were confirmed using
Factor IXa and the purified plasma proteinase inhibitors. The
inhibition of Factor IXa by ATIII was slow in the absence of
heparin. In the presence of heparin (10 U/ml) the reaction was
essentially 100% complete by I min. There was no evidence of
complex formation with either a1PI or a2M, even after 2 h
incubation with Factor IX,.
In vitro studies with human and mouse plasma confirmed
the results obtained with the purified inhibitors, as ATIII was
shown to inhibit >60% ofthe Factor IXa by 2 h, with no evidence
of Factor IXa bound to either a2M or a1PI. These results also
rule out the possibility of proteinase transfer to a2M, as described
Table IV. In Vivo Distribution of'25I-Factor IXa Among the
Plasma Proteinase Inhibitors by SDS-Polyacrylamide Gel
Electrophoresis and IgG Sepharose
% Total Factor IX.






for porcine trypsin with caPI and a2M (32). These results indicate
that ATIII is the primary inhibitor of ATIII in vitro in human
and mouse plasma. Clearance studies with mice were then un-
dertaken to determine if this result also holds in vivo. We have
recently shown that endothelial cell binding alters the proteinase
inhibitor specificity of Factor Xa, such that a2M becomes the
primary in vivo inhibitor of Factor Xa, whereas a1PI is the
primary in vitro inhibitor of Factor Xa. Recently, it has been
shown in vitro that Factor IX binds to a specific site on en-
dothelial cells and that this site can also bind Factor IXa, but
not prothrombin, thrombin, or Factor X (2, 3). The clearance
of 1251I-Factor IX was rapid and was inhibited by a large molar
excess of unlabeled Factor IX, but not by large molar excesses
of prothrombin, Factor X, DIP-thrombin, or DIP-Factor Xa.
We attempted to prepare DIP-Factor IXa for study, but were
unable to obtain this derivative even under extreme reaction
conditions. This observation agrees with previous studies by
Davie and colleagues (6).
The results of the present study are consistent with the in
vitro endothelial cell binding experiments described above. The
clearance of '251-Factor IXa was also rapid and was inhibited
by a large molar excess of unlabeled Factor IX, but not by large
molar excesses of prothrombin and Factor X. The clearance of
'251I-Factor IXa was also inhibited by large molar excesses of
DIP-thrombin and DIP-Factor Xa, indicating that Factor IXa
also binds to endothelial cell thrombin binding sites described
by Lollar and Owen (31), which we have recently shown also
bind Factor Xa (8). This result contrasts with the in vitro en-
dothelial cell binding studies described above, where thrombin
did not inhibit the binding of Factor 1Xa to endothelial cells.
This discrepancy may be due to cell damage or to loss of the
binding site during preparation of the cells for cell culture. These
results, together with the clearance and competition studies with
Factor IX, suggest that there is at least one class of endothelial
cell binding sites that recognizes the activated species Factors
IXa and Xa and thrombin, but not the zymogen forms, Factor
IX, Factor X, and prothrombin. The nature of the in vivo
thrombin binding site is unclear. One class of endothelial cell
thrombin site is thrombomodulin. The binding of thrombin to
thrombomodulin alters the substrate specificity of thrombin,
since the cleavage of fibrinogen and Factor V by thrombin bound
to thrombomodulin is drastically reduced (33). However,
thrombin bound to thrombomodulin activates protein C at least
100-fold faster than does free thrombin (34). From the data
obtained to date (2, 3, 8, 33), there is no evidence that throm-
bomodulin is the binding site for Factor Xa or Factor IXa, and
it seems from the present work that there are at least two classes
of Factor IXa binding sites. From all these observations it seems
likely that there are several classes of endothelial binding sites
that bind the vitamin K-dependent proteinases.
The possibility that the cellular elements of blood may be
involved in the catabolism of Factor IXa was investigated by
separating the plasma and cellular elements from an in vivo
blood sample by centrifugation. The plasma fraction contained
99.6% of the recovered radioactivity, indicating that the cellular
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elements of blood, such as platelets and leukocytes, are not
involved in the regulation of Factor IXa.
The role ofthe plasma proteinase inhibitors in the catabolism
of Factor IXa was examined by competition experiments with
large molar excesses of unlabeled a2M-trypsin, a1PI-trypsin,
and ATIII-thrombin complexes. The clearance pathways for
proteinase complexes of these proteinase inhibitors have been
well studied (11, 14, 15), and it has been found that proteinase
complexes of ATIII and ajPI are cleared by the same receptor
on hepatocytes (15). The clearance of '251I-Factor IX2 was not
inhibited by a large molar excess of a2M-trypsin, indicating that
a2M is not involved in the in vivo catabolism of Factor IX2.
ATIII-thrombin and a1PI-trypsin inhibited the clearance of
'25I-Factor IX2, with a1PI-trypsin providing somewhat poorer
competition. These results are consistent with the clearance of
a1PI- and ATIII-proteinase complexes by the same hepatocyte
receptor, with a1PI-trypsin complexes clearing with a longer
half-time of elimination, as previously described (15). To char-
acterize further the proteinase inhibitor-dependent phase of
Factor IX, catabolism, clearance studies were performed with
ATIII-'25I-Factor IX, complexes. The clearance of these com-
plexes was extremely rapid (50% clearance in 1.5 min) and was
inhibited by large molar excesses of unlabeled ATIII-thrombin,
and to a slightly lesser extent by aPI-trypsin, consistent with
the results described above.
Organ distribution studies with 251I-Factor IX or '251-Factor
IXa indicate that most of the recovered counts are in the liver,
an organ rich in endothelium, and also the site of binding of
ATIII-proteinase complexes.
The distribution ofFactor IXa among the plasma proteinase
inhibitors in vivo was also examined by SDS-polyacrylamide
gel electrophoresis and IgG-antiproteinase inhibitor-Sepharose
beads. These experiments demonstrate that nearly 60% of the
recovered '251-Factor IXa was in the form of the ATIII complex
after 2 min, whereas the in vitro inhibition of Factor IX2 is
considerably slower. From the data obtained in vitro in mouse
and human plasma and in vivo in the mouse, we calculated
the rate of inhibition of Factor IX2 by ATIII. There was at least
a fivefold increase in the rate of inhibition of human Factor
IX. in vivo.
Previous studies by Stern et al. (3) demonstrated that human
Factor IXa binds to bovine endothelium and has at least three
times the procoagulant activity of Factor IXa in solution. These
investigators did not examine the effect of Factor IX2 binding
on the reaction of Factor IX2 with ATIII. It is interesting that
the present data suggest a fivefold increase in binding ofhuman
Factor IXa to murine ATIII in the presence of murine endo-
thelium. While such data may not be directly comparable, both
coagulant activity and binding to ATIII involve similar active
site-substrate interactions, with ATIII functioning as a suicide
substrate. It appears, therefore, that there is considerable con-
servation of functional and binding properties of the vitamin
K-dependent proteinases, despite the different species employed
for study. These data are consistent with previous studies from
this laboratory that examined the reaction ofhuman a-thrombin
with both human and murine ATIII (1 1, 15), as well as with
studies that compared the reactivity ofhuman Factor X, to that
of ATIII from both species (8).
In summary, our data suggest that there are at least two
classes of Factor IX binding sites in vivo. One class of sites
apparently binds both Factor IX and Factor IXa, while the other
class binds the activated forms of prothrombin, Factor X, and
Factor IX.
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